FDA Clears Guardant360 Liquid CDx: First Blood Test to Combine Genomic and Epigenomic Data for Advanced Cancer Care

The new test is special because it looks at two kinds of information at the same time. It reads small changes in the DNA sequence, and it also looks at chemical marks on the DNA. These marks are called methylation. Together, the two readings help doctors choose better treatments.

Level 3 — Intermediate

The U.S. Food and Drug Administration on Wednesday cleared Guardant360 Liquid CDx, an updated version of an existing blood-based cancer test that is now the first companion diagnostic ever approved to combine genomic and epigenomic information in a single workflow. From one tube of blood, the test reads small fragments of tumor DNA that are circulating in the bloodstream, identifies cancer-driving mutations, and also detects chemical methylation patterns that indicate how cancer cells regulate their genes.

Companion diagnostics are tests that help doctors decide which targeted drugs are most likely to work for an individual patient. Until now, most companion diagnostics in oncology required a tissue biopsy. For many patients with advanced disease, tissue biopsies are painful, slow, sometimes impossible because of where the tumor sits, and often produce too little material for modern sequencing.

Adding epigenomic data to the mix lets oncologists see not only which genes are mutated but also which genes are being silenced or activated by methylation. That distinction matters because some patients carry no targetable mutations but still respond to particular therapies once their methylation profile is understood. The new test will be marketed first for non-small cell lung cancer, breast cancer, and colorectal cancer, with additional indications expected later in 2026.

Guardant Health says it has already certified more than 200 commercial laboratories in the United States to run the assay, and has begun discussions with European and Japanese regulators about parallel approvals. Industry analysts described the FDA action as a significant validation of liquid biopsy, a field that has attracted billions of dollars in investment over the past decade but has only recently begun to deliver tools that meaningfully change clinical decisions.

diagnostic: A test or tool used to identify a disease.

circulating: Moving around through the body, especially in blood.

mutation: A change in DNA that can affect how the body works.

oncology: The branch of medicine that treats cancer.

indication: A medical condition that a drug or test is officially approved to treat.

assay: A laboratory test that measures something specific.

validation: Proof that something is correct or useful.

regulator: A government body that supervises an industry.

Level 4 — Advanced

Wednesday's Food and Drug Administration clearance of Guardant360 Liquid CDx codifies what many oncologists have called the first genuinely integrated liquid biopsy: a single-tube assay that simultaneously profiles circulating tumor DNA for actionable mutations and resolves tumor-specific DNA methylation signals to a level of granularity that has, until now, required separate tissue-based workflows. The agency's review focused on the assay's analytical concordance with established tissue-genomic panels, and on prospective evidence that pairing mutation calls with methylation context refines therapy selection in late-stage solid tumors where target identification has historically been confounded by intratumoral heterogeneity.

Companion diagnostics have for two decades served as the gatekeepers of precision oncology, validating the molecular eligibility of patients for targeted therapies ranging from kinase inhibitors to PARP and immune-checkpoint regimens. The dominant paradigm has relied on histologic sampling: a needle or excisional biopsy harvests tumor tissue, which is processed for next-generation sequencing or immunohistochemistry. That model has chronically excluded a meaningful fraction of patients, including those with bone-only metastases, brain lesions in eloquent cortex, or anatomically inaccessible visceral disease, and it has generated wide repeat-biopsy attrition in adaptive trials that demand serial molecular updates.

By layering epigenomic readouts atop the conventional somatic-mutation report, Guardant360 Liquid CDx extends the actionable landscape into transcriptional silencing events that conventional sequencing alone cannot illuminate. Promoter hypermethylation of MGMT, BRCA1, and a handful of homologous-recombination loci, for example, is increasingly understood to modulate sensitivity to alkylators, PARP inhibitors, and platinum chemotherapy, even in the absence of canonical loss-of-function mutations. The integrated report is also expected to bolster early-progression detection in adjuvant settings, where minimal-residual-disease monitoring has rapidly moved from research curiosity to clinical workflow.

Commercially, the approval consolidates Guardant Health's first-mover advantage in U.S. comprehensive liquid biopsy and opens a regulatory pathway analogous to that pursued by competitors such as Natera, Personalis, and the recently-public Tempus Genomics. Reimbursement remains the principal headwind: Medicare and large commercial payers have so far covered combined genomic-epigenomic panels only narrowly, and broader uptake will hinge on whether real-world evidence demonstrates that integrated assays meaningfully reduce downstream imaging, biopsy and infusion costs. Even with those uncertainties, Wednesday's clearance is likely to be remembered as the moment when liquid biopsy formally graduated from companion to comprehensive diagnostic.

codifies: Makes a practice formal by setting it down in an official rule or standard.

concordance: The degree to which two methods agree with one another.

heterogeneity: Variation in characteristics within a population, sample, or tumor.

histologic: Relating to the microscopic examination of tissue.

attrition: Gradual loss or reduction over time, such as patients dropping out of a trial.

hypermethylation: An unusually high level of methyl groups attached to DNA, often silencing genes.

adjuvant: Additional treatment given after the main therapy to reduce risk of recurrence.

reimbursement: Payment by an insurer or payer to cover a medical service or product.

Level 1 — Absolute Beginner

Level 2 — Elementary

Level 3 — Intermediate

Level 4 — Advanced

FDA Clears Guardant360 Liquid CDx: First Blood Test to Combine Genomic and Epigenomic Data for Advanced Cancer Care

Multiple Choice

True or False

Fill in the Blank